Durvalumab vs Pembrolizumab

Durvalumab vs Pembrolizumab: Overview

This comparison examines the pharmacological differences between Durvalumab and Pembrolizumab.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Pembrolizumab — 26 days.

Chemical Properties

Type: Durvalumab — Antibody; Pembrolizumab — Antibody.